Molbio Diagnostics Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Q1 FY27 is a foundation quarter, not a growth one: Revenue of ~₹408 crores was flat QoQ, but the quarter delivered a cascade of regulatory wins (U.S. FDA for OptraScan, EU IVDR for CT/NG, HPV national program recommendation) that set up the medium-term story.
• The recurring model is now structural: ~75% of revenue now comes from test kits, confirming the razor-and-blade model has locked in; Truenat devices installed as far back as 2017-18 are still running with zero replacements, so the installed base is pure accumulation.
• OptraScan is fully derisked and fully funded: U.S. FDA clearance for the entire end-to-end workflow (machine, software, AI) makes Molbio one of only two companies globally with that certification; the business needs no additional capital for 2-3 years, though FY27 will be muted and it will not turn profitable this year.
• HPV is the next domestic catalyst, but timing is vague: Truenat HPV was the only Indian test to meet all international validation criteria, and a government health technology assessment found it cost-effective; a national program recommendation is in place, but management deferred volume and revenue guidance to next quarter.
• What to watch next quarter: Clarity on HPV rollout volumes and timing from the Government of India, initial commercialization progress for CT/NG in Europe, and any early revenue signals from OptraScan's U.S. laboratory discussions.

Regulatory & Product Catalysts

• OptraScan U.S. FDA clearance: Received in July 2026 for the entire workflow including the machine, software and AI; Molbio is among only two companies in the world with full end-to-end certification, and initial U.S. focus will target large laboratory and hospital networks where discussions are already underway.
• Prognosys regulatory progress: Secured U.S. FDA approval for a range of digital imaging solutions and EU MDR certification for X-ray products, opening developed-market pathways for the ultra-portable PRORAD system, including a planned expansion into the global companion-animal veterinary segment.
• EU IVDR certification for CT/NG: Molbio became the first Indian company to receive EU IVDR certification for its Chlamydia and Gonorrhoeae test kit, creating a regulatory bridge into European markets where commercialization plans will be clarified next quarter.
• Truenat HPV national program recommendation: An AIIMS-led validation partnered with WHO and the Gates Foundation compared multiple indigenous HPV DNA tests; Truenat was the only Indian test to meet all international criteria, and a subsequent government health technology assessment found it cost-effective at the offered price for screening women aged 30-45, triggering a recommendation to roll it out under the national program.

Shiva Sriram: "Truenat was the only test from India to meet all the international criteria, and based on which a recommendation has been made to the Government of India to roll out this test under the national program."

Revenue Model & Business Characteristics

• Recurring revenue lock-in: ~75% of revenues now come from test kits, confirming the closed-system razor-and-blade model is working as planned; Truenat reagents and consumables work only on Molbio devices and vice versa, with no third-party kits permitted.
• Device durability eliminates replacement risk: Early Truenat installations from 2017-18 are still running after 6-7 years with not a single device replaced yet, meaning the installed base grows cumulatively and no replacement cycle has begun.
• Quarterly non-linearity is structural: Q4 is typically the strongest quarter; Q1 FY27 test kit volumes were far higher than Q4 FY26, while device volumes were lower, reflecting public-health purchasing patterns that make sequential and year-on-year comparisons unreliable.
• Realization shifts are mix-driven, not price erosion: Apparent declines in per-device and per-test-kit realization reflect product mix (single-bay, two-bay, four-bay device variants) and geographical mix including dollar fluctuation benefits, not underlying price cuts; gross margins remain standard at 60-63%.

Indraneil Borkakoty: "It's not a quarter-on-quarter business because of the fact that we operate in public health, so no quarter is going to be linear, whether sequentially or year on year."

OptraScan: The U.S. Pathology Opportunity

• Regulatory milestone: U.S. FDA clearance covers the entire end-to-end workflow (machine, software, AI), making Molbio one of only two companies globally with full certification for a digital pathology system.
• Financial trajectory: FY27 is expected to be muted and the business will not turn profitable this year; meaningful contribution is expected from FY28 and FY29 onwards, and the business is already fully funded with no additional capital required for the next 2-3 years.
• Go-to-market: Initial focus will be the U.S., the world's largest pathology market, with discussions already underway with large laboratory and hospital networks.

Indraneil Borkakoty: "The business is already fully funded, and we don't see any requirement of any additional capital to grow that business over the next 2 years to 3 years."

TB: The Core Franchise Still Has Runway

• Domestic penetration gap: India currently has only 8,000-9,000 Truenat centers versus the 25,000-30,000 needed for 100% coverage; the remaining centers still use traditional microscopy, and the transition will replace that method rather than displacing a competitor.
• International expansion is just beginning: Global TB deployment is in early stages with active engagement and expansion underway; a two-year rate contract for TB was signed only last month [relative to September 8, 2026 call], valid for two years.
• Device sales outlook: FY27 device sales are expected to range between 2,200 and 2,600 units, in line with historical levels, suggesting steady rather than accelerating placement growth in the near term.

Shiva Sriram: "There's still a long pathway, as I have said earlier also, for TB, not just in India, but globally, where we are also now actively engaging and expanding our deployment."

R&D, Capacity & the Next Platform

• Capacity leverage: With minimal capex, the company can grow the top line 2x from current levels using existing capacity and the ₹72 crores of IPO automation investment, which will also deliver cost efficiencies.
• R&D direction: The bulk of R&D spend (maintained at 5-6% of revenue) will go into developing newer platforms beyond Truenat, targeting both infectious disease and non-communicable disease portfolios; only a small percentage will fund additional assays on the existing Truenat platform.
• Non-communicable disease opportunity: Management stated the total addressable universe for non-communicable disease platforms is at least 10x that of molecular tests, but declined to guide on specific platforms, timelines or revenue contribution, deferring disclosure to a future call.
• Capex outlook: No major capex is required beyond the ₹200 crores IPO allocation (₹72 crores automation, ~₹105 crores R&D center); any consolidation of Goa manufacturing facilities will be funded through internal accruals.

Chandrasekhar Nair: "We believe that Truenat is just one such platform that is needed at point of care. We have a lot more that is the need gap there is very, very high."

Export Business & Geographic Expansion

• Export trajectory: Export activity began only around 2023; past volatility reflected uneven country-level pickup, but stabilization is now occurring, and exports are expected to be a very important growth driver going forward across LMIC and developed markets.
• Developed-market entry points: Europe is accessible via the CT/NG IVDR certification; the U.S. is accessible via OptraScan (digital pathology) and Prognosys (digital imaging); commercialization timelines for CT/NG in Europe will be addressed next quarter.
• WHO prequalification for HPV: The application process is underway but noted as a long-term effort; if secured, it would enable international scaling of the HPV test in LMIC markets.
• Q1 FY27 export revenue: ~₹67 crores (16% of total) included a catch-up of deferrals from Q4 FY26 that were caused by the Gulf situation, so the quarter's export figure is not a clean run-rate.

Sriram Natarajan: "We are not competing with the centralized model and high-throughput model activities at all. We are getting into places that people don't have access to diagnosis."

Guidance & Commitments

Key Metrics